



SEDATIVE HYPNOTICS § ANTI-ANXIETY DRUGS


A sedative drug decreases activity, moderate excitement and calms the recipient

A hypnotic drug produces consciousness and facilitates onset and maintenance of a state of sleep that resembles natural sleep in its electroencephalographic characteristics and from which the recipient can be aroused easily.



① BARBITURATES

- once used extensively as sedative hypnotic.
- replaced by much safer benzodiazepines.
- described as they are prototype of CNS depressants



MOA

- GABA mimetic
- Acts on GABA: BZD receptor - chloride channel complex
- Prolongs the duration of opening of chloride channels.
- Thus potentiate GABAergic inhibition

→ pharmacological properties

- reversibly depress activity of excitable tissue
- CNS: most sensitive
 - dose dependent depression
 - sedation → sleep → Anaesthesia → coma
 - GABA facilitatory & GABA mimetic
 - ↑ binding of GABA & benzo diazepam
 - inhibit excitatory AMPA receptors
 - very high concentration: depress Na^+ & K^+ channels
- sleep
 - ↑ total sleep time
 - Alter stages of sleep
 - ↓ sleep latency; awakenings, REM & stages 3, 4
 - tolerance on repeated dose
 - discontinuation → rebound insomnia
- CVS
 - ↓ BP, HR
 - Toxicity = marked BP fall
- Anticonvulsant action
 - 5 phenyl substituent (phenobarbital, mephobarbital)
 - High anticonvulsant: sedative hypnotic ratio
 - No tolerance to this
- pain
 - No analgesia, hyperalgesia
 - ↓ pain threshold
- Respiration
 - depress respiratory drive & rhythm
- liver
 - microsomal enzyme inducer

- Tolerance

• on mood, sedation, hypnosis > anticonvulsant

- Abuse & dependence :- euphoric effects.

- PK

• well absorbed from GIT

• wide distribution

• cross placenta, secreted in milk

3 processes,

1. redistribution - Thiopentone

2. metabolism - short acting - by liver

3. excretion - long acting - unchanged in urine

- uses

• induction of anaesthesia & short surgical procedures
- Thiopentone, methohexitone (IV)

• epilepsy

> phenobarbitone - grand mal, cortical focal, status epilepticus

> Thiopentone - status epilepticus

• Hyperbilirubinaemia, kernicterus

> phenobarbitone

• Nasco analysis / Brain mapping

> Thiopentone

- A/E

> Hangover, Tolerance, dependence, confusion

> idiosyncrasy - paradoxical excitement (elderly)

- porphyria precipitation

> HS on - Asthma, urticaria, swelling of eyelids & lips, fatal exfoliative dermatitis

- C/D

• Avoid long acting - renal dysfunction

• Avoid short acting - hepatic dysfunction

• Absolute C/D : porphyrias

→ Acute barbiturate poisoning


- suicidal / accidental (drug automatism)
- excruciating CNS depression
- flabby, comatose, shallow & failing respiration, BP fall, CVS collapse, renal failure, pulmonary complication, bullous eruptions
- lethal dose: 4-3g (short acting)
5-10g (long acting)

Treatment

- Gastric lavage with activated charcoal
- supportive measures
- forced alkaline diuresis with NaHCO_3
- Hemodialysis, Hemoperfusion
- No specific antidote

→ BENZODIAZEPINES

- compound having the benzene ring fused to a seven membered diazepine ring



MOA

- GABA_A facilitatory action
- They increase the frequency of opening of GABA_A receptor Cl^- channel
- increase the affinity of GABA_A receptor for GABA
 - empty receptor is inactive and coupled chloride channel is closed
 - Binding of GABA causes the chloride ion channel to open leading to hyperpolarisation of the cell
 - binding of GABA is enhanced by benzodiazepine, resulting in greater entry of chloride ion
 - entry of Cl^- hyperpolarisation of cell, making it more difficult to depolarize, & therefore reduces neural excitability

BZD receptor ligands

- Agonist: diazepam, α compounds
- Antagonist: flumazenil
- inverse agonist: β carboline

→ pharmacological actions

I CNS actions

1. Sedation - anxiolysis

- dose dependent sedation
- useful in acute anxiety
- no tolerance to anti-anxiety effects

2. Hypnosis

- promote the onset of sleep
- $\uparrow$ total sleep time
- $\downarrow$ duration of stage 3 & 4 REM sleep
- $\uparrow$ stage 1 & 2 duration
- Tolerance develop on prolonged use

3. Anticonvulsant

- GABA mediated synaptic inhibition - anticonvulsant action
- They reduce the sustained high frequency firing of neurons similar to other anticonvulsants
- clonazepam, diazepam, lorazepam, nitrazepam
- Tolerance develops on repeated use

4. Muscle relaxant

- centrally acting skeletal muscle relaxant
- sedation limits the dose which can be used for reducing muscle tone
- Tolerance occurs to the muscle relaxant effect

II Respiration

✓ dose dependent respiratory depression

- significant only in

• extremes of age, Alcoholics, COPD, with another drug

- contraindicated in OSA

III CVS

- minimal effect except in case of intoxication
- ✓ At pre-anesthetic doses: ↓ BP & ↑ HR.

IV GIT

- ✓ decreases nocturnal gastric acid secretion; prevent stress ulcers.
- improves anxiety related GI disorders

P/K

- extensive hepatic metabolism by CYPs
- those with no CYP metabolism: OXAZEPAM / TEMAZEPAM / LORAZEPAM
- not significantly induce CYPs
- ✓ crosses placenta & secreted into milk.

ADR

- withdrawal syndrome
- ✓ Higher doses taken before labor: hypotonia, respiratory depression in neonates
- predominantly CNS effects: psychomotor impairment, ↑ reaction time, confusion, anterograde amnesia, headache, blurred vision
- ✓ epigastric distress, nausea, vomiting
- long acting agents cause residual daytime sleepiness

uses

① Anxiety disorders

CID

- pregnancy, liver diseases
- Resp depression

- Alprazolam, Lorazepam, Oxazepam, Diazepam, Chlordiazepoxide
- Oxazepam preferred in elderly as well as those with liver dysfunction
- Diazepam / Lorazepam preferred in acute panic anxiety states

✓ Insomnia

✓ Epilepsy

✓ As a skeletal muscle relaxant

✓ Alcohol withdrawal

✓ Anesthesia

D/D

- BZD potentiate other CNS depressants
- CYP3A4 inhibitors prolong action of benzodiazepines
- BZD + propofol → additive resp depression
epidural alcohol

* FLUMAZENIL

- competitive antagonist at BZD receptor
- Antagonize the binding and allosteric effects of BZD
- opposes the electrophysiological and behavioural effect of agonist & inverse agonists
- Available only for IV administration
- Hepatic metabolism
- short half life

use

- ✓ antidote for BZD overdose
- ✓ To reverse BZD induced sedative effects following anaesthesia